Papillary Adenocarcinoma — Trials

Papillary Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 48
Recruiting: 19
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07630363	PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC	not yet recruiting	Phase 1 / Phase 2	40	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Jun 5, 2026	clinicaltrials

Data updated 22 days agoSource updated Jun 5, 2026source: clinicaltrials